Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples
Arik Elfassy(Pfizer (United States)), Michael W. Pride(Pfizer (United States)), Charles Y. Tan(United States Military Academy), Kerrie Davies(University of Leeds), Michele A. Kutzler(Drexel University), Mark H. Wilcox(University of Leeds), Annaliesa S. Anderson(Pfizer (United States)), Kathrin U. Jansen(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), R. C. French(Pfizer (United States)), Há Thi Nguyen(Pfizer (United States)), Shite Sebastian(Pfizer (United States))
Cited by 12
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2017|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k